Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland

BACKGROUND: Current management of ulcerative colitis (UC) is aimed to treat active disease and to maintain remission. For patients in whom conventional treatment is no longer effective, biological or small molecule therapy may be an option. The aim was to assess the cost-effectiveness of induction a...

Descripción completa

Detalles Bibliográficos
Autores principales: Petryszyn, Pawel, Ekk-Cierniakowski, Pawel, Zurakowski, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453458/
https://www.ncbi.nlm.nih.gov/pubmed/32922513
http://dx.doi.org/10.1177/1756284820941179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453458/
https://www.ncbi.nlm.nih.gov/pubmed/32922513
http://dx.doi.org/10.1177/1756284820941179

Ejemplares similares